Authors:
Quinones, MA
Greenberg, BH
Kopelen, HA
Koilpillai, C
Limacher, MC
Shindler, DM
Shelton, BJ
Weiner, DH
Citation: Ma. Quinones et al., Echocardiographic predictors of clinical outcome in patients with Left Ventricular Dysfunction enrolled in the SOLVD Registry and Trials: Significance of left ventricular hypertrophy, J AM COL C, 35(5), 2000, pp. 1237-1244
Authors:
Slawsky, MT
Colucci, WS
Gottlieb, SS
Greenberg, BH
Haeusslein, E
Hare, J
Hutchins, S
Leier, CV
LeJemtel, TH
Loh, E
Nicklas, J
Ogilby, D
Singh, BN
Smith, W
Citation: Mt. Slawsky et al., Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure, CIRCULATION, 102(18), 2000, pp. 2222-2227
Citation: J. Ambrose et al., Angiotensin type 1 receptor antagonism with irbesartan inhibits ventricular hypertrophy and improves diastolic function in the remodeling post-myocardial infarction ventricle, J CARDIO PH, 33(3), 1999, pp. 433-439
Authors:
Gurantz, D
Cowling, RT
Villarreal, FJ
Greenberg, BH
Citation: D. Gurantz et al., Tumor necrosis factor-alpha upregulates angiotensin II type 1 receptors oncardiac fibroblasts, CIRCUL RES, 85(3), 1999, pp. 272-279
Authors:
Cohn, JN
Goldstein, SO
Greenberg, BH
Lorell, BH
Bourge, RC
Jaski, BE
Gottlieb, SO
McGrew, F
DeMets, DL
White, BG
Citation: Jn. Cohn et al., A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure, N ENG J MED, 339(25), 1998, pp. 1810-1816